Founder and Clinical Director of the Hatter Cardiovascular Institute (HCI)
A personal target when Dr Walker arrived at University College Hospital in 1987 was to attempt to restore cardiology in the hospital to something that would be fitting for an institution that had such eminent cardiologists in its recent past as Sir Thomas Lewis.
With financial help from a grateful patient, the Hatter Cardiovascular Institute was established in 1989. Dr Derek Yellon, a scientist and colleague from Dr Walker’s days at St Thomas’s Hospital, was recruited as the Director of Research. This alliance of clinical cardiology with world class scientific endeavour has continued since then with remarkable success.
The Hatter Cardiovascular Institute now has more than 20 researchers and publishes widely on the science of cardiac protection, from laboratory investigations to international clinical translational research studies, (more than 600 peer reviewed articles in the medical scientific literature within the last decade).
You can read more detailed information about two studies on this website:
- Cardiopulmonary assessment at rest and during exercise in patients with sickle cell disease (CARE-SCD);
- T1 mapping in iron overload – a new method to improve patient care.
The Hatter Cardiovascular Institute
67 Chenies Mews
London WC1E 6HX
Tel (general enquiries): 020 3447 9888
Thalassaemia & Sickle Cell Disorders
In 1990, in response to a perceived local need, Dr Walker set up a unique specialist consultant-based clinic for patients affected by inherited blood disorders, especially the thalassaemia major (TM) and sickle cell syndromes (SCD).
This clinic provides cardiology expertise and investigations for this group of patients, collaborating closely with a network of consultants in haematology at the Red Cell Disorders Unit.
The clinical experience and research emanating from this clinic has led to important publications in the medical scientific literature (see Publications section).
Most importantly our protocols, crafted after decades of providing clinical care and undertaking research, have resulted in major survival improvements, for TM patients in particular.